$AURA
Aura Biosciences, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023008166 Filed on March 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.039M $4.454M $18.06M
YoY Change 11.11% 22.09% 78.98%
% of Gross Profit
Research & Development $14.41M $13.16M $42.24M
YoY Change 74.06% 64.92% 67.87%
% of Gross Profit
Depreciation & Amortization $300.0K $323.0K $1.200M
YoY Change 0.0% 40.43% 50.0%
% of Gross Profit
Operating Expenses $14.41M $17.61M $42.24M
YoY Change 74.06% 51.48% 67.87%
Operating Profit -$19.44M -$60.30M
YoY Change 51.78% 71.05%
Interest Expense $1.978M $1.062M $1.855M
YoY Change -10510.53% -15271.43% 92650.0%
% of Operating Profit
Other Income/Expense, Net $1.978M -$8.000K $1.532M
YoY Change -8341.67% -153300.0%
Pretax Income -$17.47M -$16.56M -$58.76M
YoY Change 36.08% 42.33% 66.7%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$17.47M -$16.56M -$58.76M
YoY Change 36.08% 42.33% 66.7%
Net Earnings / Revenue
Basic Earnings Per Share -$0.46 -$1.96
Diluted Earnings Per Share -$0.46 -$0.52 -$1.96
COMMON SHARES
Basic Shares Outstanding 37.80M 29.33M 29.94M
Diluted Shares Outstanding 37.78M 29.94M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $173.5M $188.8M $188.8M
YoY Change 30.19% 26.67% 26.67%
Cash & Equivalents $38.49M $121.6M $121.6M
Short-Term Investments $135.0M $67.23M $67.23M
Other Short-Term Assets $771.0K $712.0K $7.891M
YoY Change 488.55% 978.79% 70.03%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $179.1M $196.7M $196.7M
YoY Change 28.33% 27.97% 27.97%
LONG-TERM ASSETS
Property, Plant & Equipment $5.167M $5.371M $26.04M
YoY Change -12.59% 2.29% 319.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $623.0K $423.0K $1.191M
YoY Change 398.4% 238.4% 852.8%
Total Long-Term Assets $26.90M $27.23M $27.23M
YoY Change 293.25% 330.49% 330.49%
TOTAL ASSETS
Total Short-Term Assets $179.1M $196.7M $196.7M
Total Long-Term Assets $26.90M $27.23M $27.23M
Total Assets $206.0M $223.9M $223.9M
YoY Change 40.7% 39.93% 39.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.055M $2.921M $2.921M
YoY Change -46.06% 21.66% 21.66%
Accrued Expenses $6.583M $7.211M $7.211M
YoY Change 134.69% 62.12% 62.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.107M $10.46M $10.46M
YoY Change 62.04% 43.8% 43.8%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $17.65M $17.90M $17.90M
YoY Change 5201.5% 3942.15% 3942.15%
Total Long-Term Liabilities $17.65M $17.90M $17.90M
YoY Change 5201.5% 3942.15% 3942.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.107M $10.46M $10.46M
Total Long-Term Liabilities $17.65M $17.90M $17.90M
Total Liabilities $25.76M $28.35M $28.35M
YoY Change 382.78% 267.49% 267.51%
SHAREHOLDERS EQUITY
Retained Earnings -$228.4M -$210.9M
YoY Change 38.42% 38.63%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $180.3M $195.6M $195.6M
YoY Change
Total Liabilities & Shareholders Equity $206.0M $223.9M $223.9M
YoY Change 40.7% 39.93% 39.93%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$17.47M -$16.56M -$58.76M
YoY Change 36.08% 42.33% 66.7%
Depreciation, Depletion And Amortization $300.0K $323.0K $1.200M
YoY Change 0.0% 40.43% 50.0%
Cash From Operating Activities -$16.41M -$18.01M -$54.60M
YoY Change 7.97% 49.04% 68.47%
INVESTING ACTIVITIES
Capital Expenditures $109.0K $358.0K $1.094M
YoY Change -81.8% -143.71% -48.52%
Acquisitions
YoY Change
Other Investing Activities -$66.77M -$16.52M -$66.78M
YoY Change 168.16%
Cash From Investing Activities -$66.88M -$16.88M -$67.87M
YoY Change 162.29% 1960.56% 3093.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $86.65M
YoY Change 10.11%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 201.0K 95.20M 95.63M
YoY Change 1082.35% 18.79% -42.48%
NET CHANGE
Cash From Operating Activities -16.41M -18.01M -54.60M
Cash From Investing Activities -66.88M -16.88M -67.87M
Cash From Financing Activities 201.0K 95.20M 95.63M
Net Change In Cash -83.09M 60.31M -26.84M
YoY Change 104.25% -10.3% -120.38%
FREE CASH FLOW
Cash From Operating Activities -$16.41M -$18.01M -$54.60M
Capital Expenditures $109.0K $358.0K $1.094M
Free Cash Flow -$16.52M -$18.37M -$55.70M
YoY Change 4.57% 63.05% 61.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001501796
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.072993
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-40971
CY2022 dei Entity Registrant Name
EntityRegistrantName
AURA BIOSCIENCES, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0271970
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
80 Guest Street
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
CY2022 dei City Area Code
CityAreaCode
617
CY2022 dei Local Phone Number
LocalPhoneNumber
500-8864
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
CY2022 dei Trading Symbol
TradingSymbol
AURA
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
280100000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37800102
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
121582000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149063000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
67229000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
20000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
23000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7871000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4618000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
196702000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
153704000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
768000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
125000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20671000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
950000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
423000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5371000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5251000
CY2022Q4 us-gaap Assets
Assets
223935000
CY2021Q4 us-gaap Assets
Assets
160030000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2921000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2401000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2963000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
615000
CY2022Q4 aura Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
4573000
CY2021Q4 aura Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
4339000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10457000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7355000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17895000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
360000
CY2022Q4 us-gaap Liabilities
Liabilities
28352000
CY2021Q4 us-gaap Liabilities
Liabilities
7715000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37771918
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37771918
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29211643
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29211643
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
406555000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
304452000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210900000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152137000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-72000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
195583000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
152315000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
223935000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
160030000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42238000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25161000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18057000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10089000
CY2022 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
60295000
CY2021 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
35250000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-60295000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-35250000
CY2022 us-gaap Interest Income Expense After Provision For Loan Loss
InterestIncomeExpenseAfterProvisionForLoanLoss
1864000
CY2021 us-gaap Interest Income Expense After Provision For Loan Loss
InterestIncomeExpenseAfterProvisionForLoanLoss
13000
CY2022 us-gaap Gain Loss On Investments
GainLossOnInvestments
-9000
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-318000
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-3000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1532000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-58763000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-35251000
CY2022 aura Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-58763000
CY2021 aura Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-46193000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.96
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.96
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.95
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.95
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29937228
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29937228
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5159973
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5159973
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-58763000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-35251000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-72000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-72000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58835000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35251000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-108713000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
215304000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2307000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
348000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-35251000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
152315000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
152315000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6412000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
430000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-72000
CY2022 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
62000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-58763000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
195583000
CY2022 us-gaap Profit Loss
ProfitLoss
-58763000
CY2021 us-gaap Profit Loss
ProfitLoss
-35251000
CY2022 us-gaap Depreciation
Depreciation
1177000
CY2021 us-gaap Depreciation
Depreciation
831000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
6412000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2307000
CY2022 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
527000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
22000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
CY2022 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
224000
CY2021 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
15000
CY2022 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
3253000
CY2021 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
3575000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
423000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
340000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1054000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
234000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2206000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54601000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32410000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1094000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2125000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
119784000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
53009000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-67869000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2125000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
78697000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
86650000
CY2022 aura Proceeds From Issuance Of Common Stock Under At The Market Facility Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockUnderAtTheMarketFacilityNetOfIssuanceCosts
8549000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
430000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
349000
CY2021 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-15000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
95629000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
166259000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26841000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
131724000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
149211000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17487000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
122370000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
149211000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
180000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
386000
CY2021 aura Initial Measurement Of Right Of Use Assets And Lease Liabilities For Operating Lease
InitialMeasurementOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLease
536000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
21210000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
516000
CY2021 aura Remeasurement Of Right Of Use Assets And Lease Liabilities For Lease Modification
RemeasurementOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseModification
390000
CY2021 aura Deferred Offering Costs In Accounts Payable
DeferredOfferingCostsInAccountsPayable
377000
CY2022 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
-296000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
121582000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149063000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
20000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
23000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
768000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
125000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122370000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
149211000
CY2021Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On October 22, 2021, the Company effected a reverse stock split of the Company’s common stock on a 1-for-13.7 basis, or the Reverse Stock Split.
CY2022Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
250000000.0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-58800000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-35300000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
188800000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210900000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant items subject to such estimates and assumptions include the fair value of stock-based compensation and accrued research and development costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 aura Prepaid License Agreements
PrepaidLicenseAgreements
64000
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
800000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
712000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
66000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7871000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4618000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
67302000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
20000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9235000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8015000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3864000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2764000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5371000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5251000
CY2022 us-gaap Depreciation
Depreciation
1200000
CY2021 us-gaap Depreciation
Depreciation
800000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2174000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2734000
CY2022Q4 aura Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
4982000
CY2021Q4 aura Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1754000
CY2022Q4 aura Prepaid License Agreements
PrepaidLicenseAgreements
3000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
93000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
67229000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
100000
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q4 aura Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1543000
CY2021Q4 aura Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1686000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2705000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2147000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
325000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
506000
CY2022Q4 aura Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
4573000
CY2021Q4 aura Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
4339000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37771918
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37771918
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29211643
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29211643
CY2021Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2021Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
250000000.0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.79
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.84
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
800000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0300
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0115
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M28D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7810
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7387
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y7M2D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M29D
CY2021Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0794
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1071
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0351
CY2022Q4 aura Deferred Tax Asset Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetDeferredExpenseCapitalizedResearchAndDevelopmentCosts
39000000.0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6412000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2307000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
13500000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M14D
CY2021Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
4516
CY2021Q1 aura Lease Commencement Date
LeaseCommencementDate
2021-05-01
CY2021Q1 aura Additional Area Of Rented Space
AdditionalAreaOfRentedSpace
1000
CY2021Q1 aura Additional Leased Space Commencement Date
AdditionalLeasedSpaceCommencementDate
2021-06-15
CY2021Q1 aura Operating Lease Termination Date
OperatingLeaseTerminationDate
2023-07-31
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P12M
CY2021 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
11000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1879000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
524000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
1258000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
322000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000
CY2022 us-gaap Lease Cost
LeaseCost
3145000
CY2021 us-gaap Lease Cost
LeaseCost
861000
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
15000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1690000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
519000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3111000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3205000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3301000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3400000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3502000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
17430000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
33949000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
13091000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
20858000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2963000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17895000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-58763000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-35251000
CY2021 us-gaap Dividends Preferred Stock
DividendsPreferredStock
10942000
CY2022 aura Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-58763000
CY2021 aura Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-46193000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29937228
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29937228
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5159973
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5159973
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.96
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.96
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.95
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.95
CY2021Q4 aura Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
241000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
207000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
182000
CY2022Q4 aura Deferred Tax Liabilities Accrued Expenses
DeferredTaxLiabilitiesAccruedExpenses
93000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
60032000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
43279000
CY2022 aura Federal Net Operating Loss Carryback Percentage Limited To Income In Any Year
FederalNetOperatingLossCarrybackPercentageLimitedToIncomeInAnyYear
0.80
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
60000000.0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
16800000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4469972
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4477597
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.056
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.053
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.029
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.026
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.011
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.004
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.003
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.285
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.282
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
40617000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
36287000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1235000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
635000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
10200000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
7924000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
5821000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
517000
CY2022Q4 aura Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
5461000
CY2021Q4 aura Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
248000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
307000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
194000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
65744000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
43702000
CY2022Q4 aura Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
5412000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
0

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-008166-index-headers.html Edgar Link pending
0000950170-23-008166-index.html Edgar Link pending
0000950170-23-008166.txt Edgar Link pending
0000950170-23-008166-xbrl.zip Edgar Link pending
aura-20221231.htm Edgar Link pending
aura-20221231.xsd Edgar Link pending
aura-ex21_1.htm Edgar Link pending
aura-ex23_1.htm Edgar Link pending
aura-ex31_1.htm Edgar Link pending
aura-20221231_cal.xml Edgar Link unprocessable
aura-20221231_def.xml Edgar Link unprocessable
aura-20221231_pre.xml Edgar Link unprocessable
aura-20221231_lab.xml Edgar Link unprocessable
aura-20221231_htm.xml Edgar Link completed
aura-ex31_2.htm Edgar Link pending
aura-ex32_1.htm Edgar Link pending
aura-ex4_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img249090919_0.jpg Edgar Link pending
img249090919_1.jpg Edgar Link pending
img249090919_10.jpg Edgar Link pending
img249090919_11.jpg Edgar Link pending
img249090919_12.jpg Edgar Link pending
img249090919_13.jpg Edgar Link pending
img249090919_2.jpg Edgar Link pending
img249090919_3.jpg Edgar Link pending
img249090919_4.jpg Edgar Link pending
img249090919_5.jpg Edgar Link pending
img249090919_6.jpg Edgar Link pending
img249090919_7.jpg Edgar Link pending
img249090919_8.jpg Edgar Link pending
img249090919_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending